Neogenomics, Inc. (NGNM) Cash Flow Statement

Click line-items for a historical chart and %

Net (loss)	500K
Provision for bad debts	8.18M
Depreciation	11.55M
Amortization of debt issue costs	532K
Stock-based compensation
(Increase) decrease in accounts receivable, net of write-offs	-9.42M
(Increase) decrease in inventories	-844K
(Increase) decrease in other current assets	-46K
(Increase) decrease in deposits
Increase (decrease) in accounts payable, accrued expenses and other liabilities	3.27M
NET CASH USED IN OPERATING ACTIVITIES
Purchases of property and equipment	-5.33M
NET CASH USED IN INVESTING ACTIVITIES
Proceeds from capital lease obligations
Advances on credit facility
Repayment of capital leases and loans	-3.87M
Decrease in restricted cash
Issuance of common stock, net of transaction costs
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	5.52M
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	23.42M
CASH AND CASH EQUIVALENTS, END OF PERIOD	28.94M
Interest paid	3.99M
Income taxes paid	228K
Equipment leased under capital leases	4.91M

Entities mentioned with NGNM

View All Entities